United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - probenecid (unii: po572z7917) (probenecid - unii:po572z7917), colchicine (unii: sml2y3j35t) (colchicine - unii:sml2y3j35t) - probenecid 500 mg - for the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout. hypersensitivity to this product or to probenecid or colchicine. probenecid and colchicine tablets are contraindicated in children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid and colchicine should not be started until an acute gouty attack has subsided. pregnancy: probenecid crosses the placental barrier and appears in cord blood. colchicine can arrest cell division in animals and plants. in certain species of animal under certain conditions, colchicine has produced teratogenic effects. the possibility of such effects in humans also has been reported. because of the colchicine component, probenecid and colchicine is contraindicated in pregnant patients. the use of any drug in women of child bearing potential requires that the anticipated benefit be weighed against the possible hazards.

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - probenecid (unii: po572z7917) (probenecid - unii:po572z7917), colchicine (unii: sml2y3j35t) (colchicine - unii:sml2y3j35t) - probenecid 500 mg - for the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout. hypersensitivity to this product or to probenecid or colchicine. probenecid and colchicine tablets are contraindicated in children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid and colchicine should not be started until an acute gouty attack has subsided. probenecid crosses the placental barrier and appears in cord blood. colchicine can arrest cell division in animals and plants. in certain species of animals under certain conditions, colchicine has produced teratogenic effects. the possibility of such effects in humans also has been reported. because of the colchicine component, probenecid and colchicine is contraindicated in pregnant patients. the use of any drug in women of childbearing potential requires that the anticipated benefit be weighed against the possible hazards.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - probenecid 500mg;  ;  ;  ;  ; probenecid 500mg; probenecid 500mg - film coated tablet - 500 mg - active: probenecid 500mg         excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose opadry clear ys-1-7006 opadry yellow ys-1-2063 povidone sodium starch glycolate stearic acid active: probenecid 500mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose opadry clear ys-1-7006 opadry yellow ys-1-2063 povidone sodium starch glycolate stearic acid active: probenecid 500mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose opadry clear ys-1-7006 opadry yellow ys-1-2063 povidone sodium starch glycolate stearic acid - · probenecid is a uricosuric agent for the treatment of hyperuricaemia in all stages of gout and gouty arthritis except a presenting acute attack. asymptomatic hyperuricaemia seems to occur in a significant percentage of relatives of gouty patients. probenecid may be given prophylactically to these people to forestall gouty attacks and urate deposition in tissues. by virtue of its effective uricosuric activity, probenecid may be used to control the hyperuricaemia induced or aggravated by many diuretics employed for the treatment of oedema and hypertension (e.g. thiazides and similar diuretics).

United States - English - NLM (National Library of Medicine)

marlex pharmaceuticals inc - probenecid (unii: po572z7917) (probenecid - unii:po572z7917) - probenecid 500 mg - probenecid tablets are indicated for the treatment of the hyperuricemia associated with gout and gouty arthritis. as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. hypersensitivity to probenecid. children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid should not be started until an acute gouty attack has subsided.

United States - English - NLM (National Library of Medicine)

american health packaging - probenecid (unii: po572z7917) (probenecid - unii:po572z7917) - probenecid 500 mg - probenecid tablets are indicated for the treatment of the hyperuricemia associated with gout and gouty arthritis. as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. hypersensitivity to probenecid. children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid should not be started until an acute gouty attack has subsided.

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - probenecid (unii: po572z7917) (probenecid - unii:po572z7917) - probenecid 500 mg - probenecid tablets are indicated for the treatment of the hyperuricemia associated with gout and gouty arthritis. as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. hypersensitivity to probenecid. children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid should not be started until an acute gouty attack has subsided.

United States - English - NLM (National Library of Medicine)

lannett company, inc. - probenecid (unii: po572z7917) (probenecid - unii:po572z7917) - probenecid 500 mg - probenecid tablets are indicated for the treatment of the hyperuricemia associated with gout and gouty arthritis. as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. hypersensitivity to probenecid. children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid should not be started until an acute gouty attack has subsided.

United States - English - NLM (National Library of Medicine)

hhs/program support center/supply service center - probenecid (unii: po572z7917) (probenecid - unii:po572z7917) - probenecid 500 mg - for treatment of the hyperuricemia associated with gout and gouty arthritis. as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. hypersensitivity to probenecid. children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid should not be started until an acute gouty attack has subsided.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - probenecid (unii: po572z7917) (probenecid - unii:po572z7917) - probenecid 500 mg - probenecid tablets are indicated for the treatment of the hyperuricemia associated with gout and gouty arthritis. as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. hypersensitivity to probenecid. children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid should not be started until an acute gouty attack has subsided.

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - probenecid (unii: po572z7917) (probenecid - unii:po572z7917), colchicine (unii: sml2y3j35t) (colchicine - unii:sml2y3j35t) - for the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout. hypersensitivity to this product or to probenecid or colchicine. probenecid and colchicine tablets are contraindicated in children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid and colchicine should not be started until an acute gouty attack has subsided. pregnancy: probenecid crosses the placental barrier and appears in cord blood. colchicine can arrest cell division in animals and plants. in certain species of animals under certain conditions, colchicine has produced teratogenic effects. the possibility of such effects in humans also has been reported. because of the colchicine component, probenecid and colchicine is contraindicated in pregnant patients. the use of any drug in women of childbearing potential requires that the anticipated benefit be weighed against the possible hazards.